镰状细胞性贫血是一种血红蛋白病,可引起诸如Vaso闭塞性危机(VOC)等并发症,中风,阴茎异常勃起,急性胸部综合征(ACS),血管阻塞引起的骨梗死,导致缺氧,缺血,和炎症。预防这些事件可以提高镰状细胞病(SCD)患者的生活质量并降低死亡率。本系统综述旨在描述药物,他们的行动机制,剂量,血红蛋白参数的变化,VOCs减少,延迟下一个VOC的时间,减少住院时间,以及与这些药物相关的副作用。本审查符合系统审查和荟萃分析(PRISMA)2020指南的首选报告项目。对于这篇评论,我们搜索了PubMed,谷歌学者,和Cochrane数据库,并从2018年开始的过去五年中筛选以英语发表并在人类中进行研究的完整免费文本。随机临床试验(RCT),观察性研究,荟萃分析,系统审查,和传统的评论都包含在搜索中。根据研究的类型,使用质量评估工具,选择了八篇论文。对这些论文的全文文章进行了研究,分析,并制成表格。我们讨论了七种用于治疗镰状细胞病的干预措施。voxelotor,crizanlizumab,L-谷氨酸,长期输血,锌(Zn),Niprisan®,发现Ciklavit*可降低VOC的数量和严重程度。我们发现含有L-谷氨酸的VOCs缩短了住院时间。镁(Mg)不影响VOCs的数量和严重程度。这篇综述包括了该研究的几篇文章。关于这个主题的未来论文应该包括大样本量和许多论文。需要更多的临床试验来评估联合使用这些药物预防VOC的剂量和结果。
Sickle cell anemia is a hemoglobinopathy that causes complications such as Vaso-Occlusive Crisis (VOC), stroke, priapism, Acute Chest Syndromes (ACS), and bone infarcts due to blood vessel occlusion, resulting in hypoxia, ischemia, and inflammation. Preventing these incidents improves the quality of life and lowers mortality rates in Sickle Cell Disease (SCD) patients. This systematic review aims to describe the drugs, their mechanisms of action, dosages, changes in hemoglobin parameters, decrease in VOCs, delay the time for the next VOC, decrease in the length of hospital stay, and side effects associated with these drugs. This review adheres to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. For this review, we searched the PubMed, Google Scholar, and Cochrane databases and screened them for full free texts published in English and studied in humans in the last five years beginning in 2018. Randomized clinical trials (RCT), observational studies, meta-analyses, systemic reviews, and traditional reviews were all included in the search. According to the type of study, quality assessment tools are used, and eight papers are chosen. Full-text articles from these papers are studied, analyzed, and tabulated. We discussed seven interventions that are used to treat sickle cell disease.
Voxelotor, crizanlizumab, L-glutamate, long-term blood transfusions, Zinc (Zn), Niprisan®, and Ciklavit* were found to reduce the number and severity of VOC. We discovered that VOCs containing L -glutamate reduced the length of hospitalization. Magnesium (Mg) did not affect the number and severity of VOCs. This review includes a few articles for the study. Future papers on this subject should include a large sample size and many papers. More clinical trials are required to evaluate the dosages and outcomes of using these drugs in combination to prevent VOCs.